Enginzyme completes series A financing

The Swedish biotechnology company EnginZyme AB has completed its Series A financing round, led by the life science VC Sofinnova Partners. The funds raised will primarily be used for further development and commercialization of the company’s technology platform.

EnginZyme was advised by Mannheimer Swartling in the transaction.


This website uses cookies to perform certain functions and help you navigate the site efficiently. A cookie is a text file with a small amount of information that is stored on your device. We share some of the information we obtain through these cookies with third parties. We only use cookies that are necessary for the site to function correctly and they therefore cannot be turned off. For further information, see Information on the use of cookies.